SCHEMBL22152109

SCHEMBL22152109

Cc1cc(N)nc(N2CCO[C@@H](C)C2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
ATM Q13315 2/20 0.42
NR3C2 P08235 1/20 0.42
PIK3CB P42338 7/20 0.41
PIK3CD O00329 6/20 0.41
PIK3CG P48736 6/20 0.41
PIK3CA P42336 6/20 0.41
MAP3K12 Q12852 1/20 0.41
KIF18A Q8NI77 4/20 0.41
MTOR P42345 1/20 0.40
LRRK2 Q5S007 3/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22122544 1.00 GRIN2D (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22122546 1.00 GRIN2D (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22122463 0.82 KIF18A (0.40) ATMNR3C2PIK3CBPIK3CDPIK3CG
SCHEMBL22122464 0.82 KIF18A (0.40) ATMNR3C2PIK3CBPIK3CDPIK3CG
SCHEMBL22122495 0.81 PIK3CD (0.43) ATMNR3C2PIK3CBPIK3CDPIK3CG
SCHEMBL22122456 0.81 LRRK2 (0.46) ATMNR3C2PIK3CBPIK3CDPIK3CG
SCHEMBL22122457 0.81 LRRK2 (0.46) ATMNR3C2PIK3CBPIK3CDPIK3CG
SCHEMBL22122493 0.81 PIK3CD (0.43) ATMNR3C2PIK3CBPIK3CDPIK3CG
SCHEMBL30637270 0.79 RBP4 (0.45) ATMNR3C2PIK3CDPIK3CGKIF18A
SCHEMBL22121021 0.79 CRHBP (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459932-B2 KIF18A inhibitors AMGEN INC. (US) 2025-11-04 US disclosed
EP-3897855-B1 KIF18A INHIBITORS AMGEN INC (US) 2023-06-07 EP disclosed
US-20220073504-A1 KIF18A INHIBITORS AMGEN INC. (US) 2022-03-10 US disclosed
US-20220073504-A1 KIF18A INHIBITORS AMGEN INC. (US) 2022-03-10 US disclosed
WO-2020132651-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073504-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 GRIN2D 4017/4885GRIN3B 3527/4885GRIN1 2828/4885
US-12459932-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 GRIN2D 4017/4885GRIN3B 3527/4885GRIN1 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.